M&A Trends by Industry: A Practitioner's Survey

This is a single substantive replacement for the per-industry M&A trend stubs the Mage blog used to carry as separate pages. Diligence patterns are stable enough across years that a one-stop survey serves attorneys better than thirty templated single-paragraph posts. We retire the stubs in favor of this guide and a smaller set of deep one-offs where the sector genuinely warrants it.

The structure is the same for every industry we cover: what makes the diligence different, the recurring traps, the regulatory layer, the integration realities, and what AI-augmented diligence changes about the work.

Technology and SaaS

Tech M&A is dominated by intangibles: IP assignment chain integrity, open-source license compliance, and customer concentration. Financial diligence matters but less than provenance.

The recurring traps:

• IP assignment chain breaks at the founder layer. The most common pattern: founder builds the prototype before incorporation, never re-assigns. Pre-incorporation IP can be carved out by a careful PSA, but the underlying problem is that a meaningful chunk of the target's IP may not actually belong to the target. Verify every founder, every senior engineer, has a clean assignment that pre-dates the prototype work.
• Open-source license non-compliance. Targets routinely use GPL or AGPL components in proprietary products without recognizing the obligations. A buy-side discovery here is a re-architect-or-renegotiate problem. Run a software composition analysis (SCA) on the codebase early; do not wait until weeks before signing.
• Customer concentration and change-of-control. SaaS targets often have a top-5 that's 40-60% of revenue. If those contracts have anti-assignment language, the buyer is buying a contingent revenue stream. We covered this in What 300 NDAs Taught Me About Change-of-Control Clauses for the NDA layer, but the issue is much sharper for paying customers.
• Auto-renewal and price-protection clauses. SaaS targets win deals by giving customers price protection ("won't increase more than CPI") or perpetual auto-renewal. These compound and create deferred revenue that's not really discretionary.
• AI training rights. A new vintage of customer contracts started restricting whether the target can train models on customer data. For an AI-using target, this is a forward-looking IP rights problem.

Regulatory layer: HSR for material deals, CFIUS if foreign acquirer + sensitive technology (defense, AI, biotech, semiconductors), state-level data privacy (CCPA, etc.) review of customer-data handling.

Integration reality: Tech-stack consolidation is the cited synergy; the unspoken cost is platform-migration drag on the engineering team for 12-24 months post-close. Plan for it.

Healthcare and life sciences

Healthcare M&A is regulatory-first. The best commercial terms in the world don't matter if the target operates licenses or accepts reimbursement under arrangements that don't survive a change of control.

The recurring traps:

• CMS provider numbers and Medicare/Medicaid enrollment. Many target structures require new provider-number applications post-close, which can take months. The diligence question is whether the target can keep operating during the transition.
• HIPAA Business Associate Agreements. Every BAA in the chain has change-of-control provisions; a slip means the target's protected health information rights aren't transferable.
• Stark Law and Anti-Kickback exposure. Physician-arrangement contracts (employment, real estate leases, equipment, services) get scrutinized. A buyer inheriting non-compliant arrangements inherits the qui-tam suit risk.
• 340B drug pricing. For hospital-affiliated targets. Arrangements have to be re-papered; eligibility doesn't automatically transfer.
• State-level licensing. Particularly in long-term care, behavioral health, and home health. Each state's transfer or relicensure rules are different, and the timeline can drive the closing date.

Regulatory layer: HSR (often), state DOH approvals, FTC scrutiny on hospital and physician-group consolidation, CMS for Medicare-certified facilities, FDA for device/drug-related deals.

Integration reality: Healthcare integrations frequently fail on EMR/IT stack incompatibility before they fail on culture. Allocate real budget for the system migration before signing the IOI.

Financial services and fintech

Financial services M&A is permission-first, then capital-first, then commercial.

The recurring traps:

• Bank Holding Company Act and CIBC Act consents for bank-affiliated buyers and targets. Multi-month timelines.
• State money transmitter licenses for fintech targets. Each state's transfer rules differ; some require new applications, some surrender-and-reissue, some allow assignment.
• OFAC, BSA/AML, sanctions screening. A target with weak controls inherits a remediation cost the seller did not price into the deal.
• Customer-data privacy. GLBA on consumer financial info, Reg P notices on changes of control, plus CCPA / state privacy regimes layered on top.
• Capital and prudential thresholds. Acquiring entity may need to raise capital or restructure to satisfy Tier 1 ratios after the deal closes.

Regulatory layer: HSR, Fed/OCC/FDIC for bank deals, state insurance commissioners for insurance deals, FINRA for broker-dealer deals, SEC for advisor deals, CFPB scrutiny on consumer-finance targets.

Integration reality: Compliance program harmonization is the work. The acquired entity's BSA/AML and sanctions-screening posture becomes the consolidated entity's posture; running on two programs in parallel is a recipe for findings.

Manufacturing and industrials

Manufacturing M&A is asset-heavy: plant condition, environmental compliance, working-capital normalization, and labor exposure dominate.

The recurring traps:

• Phase I Environmental Site Assessments (and Phase II if Phase I surfaces issues). Every owned or leased site. Missing the ASTM E1527-21 ≤180-day window forfeits Bona Fide Prospective Purchaser, Innocent Landowner, and Contiguous Property Owner defenses. We can't overstate how often this gets compressed and creates real CERCLA exposure.
• Union exposure. Successor liability under labor agreements, pension multi-employer withdrawal liability, ERISA underfunding. The withdrawal liability can be a deal-breaker on its own.
• Working-capital adjustments are real money. Inventory normalization (FIFO vs. LIFO, slow-moving categorization), AR aging, prepaid maintenance amortization. The seller's "trailing twelve months" picture often masks meaningful one-offs.
• Customer purchase-order contracts. Manufacturing targets often have framework agreements plus rolling POs. The framework's change-of-control language matters, but so do the POs themselves; some have unilateral termination rights for the customer.
• Supplier dependency and concentration. Single-source supplier relationships are operational risks the buyer inherits.

Regulatory layer: HSR, OSHA enforcement history, EPA/state environmental permits, DOT for transportation-adjacent businesses, BIS and ITAR for export-controlled products.

Integration reality: Plant consolidation politics are the integration. Communicate which sites are staying and which are closing within 90 days, ideally pre-close.

Real estate

Real estate M&A is title-first, environmental-second, lease-third. The corporate veneer matters less than the asset condition.

The recurring traps:

• Title defects, easements, encroachments. Every parcel needs a title commitment. A messy title chain on a single material parcel can cost the buyer the deal, the financing, or both.
• Phase I ESAs on every owned site. Same as manufacturing.
• Lease assignment language. Commercial leases often require landlord consent for change-of-control. Sublease, assignment, and non-disturbance rights all matter.
• Estoppel certificates and subordination agreements. Required for financing; gathering them is operationally heavy and often lands at the worst time pre-close.
• Property tax reassessment risk. Some states reassess on transfer (California's Prop 13 + Prop 19 mechanics, for instance). Plan for the tax bump.
• Zoning and entitlement transferability. Especially for development-stage assets.

Regulatory layer: HSR (rarely), state-level real estate transfer taxes, FIRPTA for foreign sellers, RESPA for residential platforms.

Integration reality: Property management consolidation. Decisions about in-house vs. third-party management on each property drive the next 12 months of operating expense.

Energy and infrastructure

Energy M&A is regulatory-permitting-first. Underlying assets are often valuable but tied to consents that don't transfer cleanly.

The recurring traps:

• FERC consents for generation, transmission, midstream pipeline assets. Multi-month timelines.
• State PUC consents for utility-affiliated assets.
• Power Purchase Agreements are the revenue stream; their change-of-control, credit-support, and step-in rights matter as much as their economics. We covered the broader review pattern in How to Review Power Purchase Agreements.
• Commodity-hedging contracts. Step-in rights for the counterparty on change-of-control; collateral-call mechanics under stress.
• Decommissioning liability. Particularly for nuclear, oil-and-gas, and offshore wind. The buyer inherits the long-tail liability and needs to verify the trust funding.
• Indigenous-rights and surface-use agreements. Often the operational pinch-point.

Regulatory layer: HSR, FERC, state PUCs, BLM and BIA for federal-land assets, EPA, DOE for some technologies.

Integration reality: Asset-level operational data integration. ERP, SCADA, and metering systems often don't talk to each other.

Aerospace and defense

Defense M&A is national-security-first. The buyer needs CFIUS clearance and often DSS/DCSA mitigation.

The recurring traps:

• CFIUS jurisdiction. Mandatory in many cases; voluntary filing is the safe move when there is any non-US capital in the buyer's stack.
• Industrial security clearance continuity. A facility security clearance (FSL) does not automatically survive a change of control. Special Security Agreements, voting trusts, and proxy boards are common mitigations.
• Export controls (ITAR, EAR). Every product needs to be classified. A misclassification carries criminal liability.
• DCAA-audited cost accounting standards (CAS) compliance for cost-plus contracts.
• Unallowable cost categorization. A buyer inheriting a target with sloppy CAS practice inherits the disallowance + interest exposure.

Regulatory layer: HSR, CFIUS, DSS/DCSA, State Department (ITAR), Commerce (EAR), DCAA for cost-type contractors.

Integration reality: Cleared facility integration takes longer than the corporate close. Plan for a 6-18 month tail.

Consumer products and retail

Consumer M&A is brand-and-channel-first. The valuation rests on the brand equity, but the diligence finds problems in the supply chain.

The recurring traps:

• Trademark portfolio holes. Targets often own the US mark but not the international ones, or have incomplete coverage in product categories they actually sell in.
• Influencer / endorsement contracts. Frequently informal, frequently with morality clauses that are hard to enforce, often with auto-renew.
• Channel-of-distribution contracts (Amazon, Walmart, Target). Margin floors, MAP policies, returns and chargebacks. Buyer assumes them; not all are obvious from the financials.
• Product liability tail. Particularly for products with long use-life. Insurance retro-coverage and reps-and-warranties insurance gap analysis is critical.
• Class-action exposure for false advertising, slack-fill, biometric privacy (BIPA in Illinois). Look at filed and threatened actions.

Regulatory layer: HSR, FTC for marketing claims, FDA for food/cosmetics/OTC, state AG actions, CPSC for product safety.

Integration reality: Distribution-network rationalization is where the synergies live and where the customer relationships break.

Private equity add-ons

PE add-on M&A is platform-thesis-first. The diligence question is whether the target plugs into the existing platform without breaking it.

The recurring traps:

• System fit. ERP, accounting, billing systems often don't reconcile cleanly. Integration cost is non-trivial.
• Customer overlap. Are top customers also customers of the platform? Discount-stacking and most-favored-customer issues can surface.
• Geographic and regulatory overlap. Same as above for territories and licenses.
• Earnouts and rollover equity. Common in add-ons and a recurring source of post-close litigation if the integration changes the basis on which the earnout was earned.
• Founder-departure risk. Many add-ons are founder-led; the deal is contingent on the founder's transition. Non-compete and consulting-agreement terms matter as much as the headline price.

Regulatory layer: same as the underlying industry, scaled to the add-on's size.

Integration reality: 100-day plans. PE platforms have a script; align the target's first 100 days to it before close.

What AI-augmented diligence changes about the industry-specific layer

Two things, one obvious and one less so.

The obvious one is leverage. A configurable risk-checklist library that covers all twelve industries above lets a deal team run the right list against the right target on Day 1, without rebuilding the list from scratch on every deal. Configure once, reuse forever. We described the operational mechanics in our AI Due Diligence playbook.

The less obvious one is cross-pollination. A target that straddles industries (a fintech with healthcare customers, a SaaS embedded in defense, a manufacturer with a software product) needs both lists. Manual diligence routinely picks one and misses the other. AI-augmented diligence runs both and surfaces the overlap as findings the partner can prioritize.

For the broader category of how legal AI fits the M&A workflow end-to-end, see the Legal AI for M&A master guide. For tool-evaluation specifics, see Evaluating Legal AI Tools.

If you have a current deal in any of these industries and want to see how Mage handles it, request a demo. Bring the data room. We will run a sector-appropriate first pass and walk you through what we find.